BioTech
Manufacturers need to be more open about a dangerous Alzheimer’s drug side effect
Since the FDA’s approval of lecanemab (marketed as Leqembi) and Medicare’s recent decision to cover the drug, I have met with Alzheimer’s patients and their
Madhav Thambisetty
November 28, 2023